Callan Capital LLC Invests $192,000 in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Callan Capital LLC bought a new position in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK) during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 13,451 shares of the company’s stock, valued at approximately $192,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. XY Capital Ltd lifted its holdings in Takeda Pharmaceutical by 432.5% during the fourth quarter. XY Capital Ltd now owns 765,137 shares of the company’s stock worth $10,919,000 after acquiring an additional 621,440 shares in the last quarter. FMR LLC lifted its holdings in Takeda Pharmaceutical by 4.7% during the third quarter. FMR LLC now owns 2,593,350 shares of the company’s stock worth $40,119,000 after acquiring an additional 115,947 shares in the last quarter. Brandes Investment Partners LP lifted its holdings in Takeda Pharmaceutical by 2.1% during the third quarter. Brandes Investment Partners LP now owns 1,802,036 shares of the company’s stock worth $27,877,000 after acquiring an additional 36,717 shares in the last quarter. Citigroup Inc. raised its stake in shares of Takeda Pharmaceutical by 5.6% in the 3rd quarter. Citigroup Inc. now owns 57,941 shares of the company’s stock valued at $896,000 after purchasing an additional 3,089 shares during the period. Finally, Schonfeld Strategic Advisors LLC acquired a new stake in shares of Takeda Pharmaceutical in the 3rd quarter valued at about $2,105,000. 9.17% of the stock is currently owned by institutional investors.

Takeda Pharmaceutical Stock Down 0.3 %

Shares of TAK traded down $0.04 during midday trading on Friday, hitting $13.03. The stock had a trading volume of 1,213,476 shares, compared to its average volume of 1,688,482. The company has a 50 day simple moving average of $14.06 and a two-hundred day simple moving average of $14.20. Takeda Pharmaceutical Company Limited has a twelve month low of $13.01 and a twelve month high of $17.11. The firm has a market cap of $41.24 billion, a price-to-earnings ratio of 19.75, a price-to-earnings-growth ratio of 2.98 and a beta of 0.53. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.06 and a quick ratio of 0.55.

Takeda Pharmaceutical (NYSE:TAK) last released its quarterly earnings results on Thursday, February 1st. The company reported $0.51 earnings per share (EPS) for the quarter. The firm had revenue of $7.52 billion for the quarter. Takeda Pharmaceutical had a return on equity of 12.57% and a net margin of 6.90%. On average, analysts anticipate that Takeda Pharmaceutical Company Limited will post 1.5 EPS for the current year.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.